Secondary prevention of acute coronary syndromes: a summary of the new 2025 Australian guideline.

IF 4.2 Q2 PHARMACOLOGY & PHARMACY

Australian Prescriber Pub Date : 2026-02-01 DOI:10.18773/austprescr.2026.008

Jasmine Just, David Brieger, Alexandra Bennett, Tom Briffa

{"title":"Secondary prevention of acute coronary syndromes: a summary of the new 2025 Australian guideline.","authors":"Jasmine Just, David Brieger, Alexandra Bennett, Tom Briffa","doi":"10.18773/austprescr.2026.008","DOIUrl":null,"url":null,"abstract":"<p><p>Acute coronary syndromes (ACS) remain a significant cause of disability and death in Australia. Following an initial acute coronary event, there is a significant risk of recurrence, particularly in the first 90 days. In April 2025, the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand launched a new Australian clinical guideline for diagnosing and managing ACS. The guideline includes recommendations for the secondary prevention of ACS. Pharmacotherapies for secondary prevention of ACS include antiplatelet and anticoagulant drugs, lipid-modifying therapy, beta blockers and renin-angiotensin antagonist therapies, plus - in select groups - colchicine and other therapies. Vaccination against influenza and other respiratory pathogens is recommended. Nonpharmacological interventions include cardiac rehabilitation, healthy behaviour changes and screening for mental health conditions. The importance of providing strategies to support adherence to long-term therapies is also emphasised.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 1","pages":"30-35"},"PeriodicalIF":4.2000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12928837/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18773/austprescr.2026.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Acute coronary syndromes (ACS) remain a significant cause of disability and death in Australia. Following an initial acute coronary event, there is a significant risk of recurrence, particularly in the first 90 days. In April 2025, the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand launched a new Australian clinical guideline for diagnosing and managing ACS. The guideline includes recommendations for the secondary prevention of ACS. Pharmacotherapies for secondary prevention of ACS include antiplatelet and anticoagulant drugs, lipid-modifying therapy, beta blockers and renin-angiotensin antagonist therapies, plus - in select groups - colchicine and other therapies. Vaccination against influenza and other respiratory pathogens is recommended. Nonpharmacological interventions include cardiac rehabilitation, healthy behaviour changes and screening for mental health conditions. The importance of providing strategies to support adherence to long-term therapies is also emphasised.

查看原文本刊更多论文

急性冠状动脉综合征的二级预防：新2025澳大利亚指南摘要

在澳大利亚，急性冠状动脉综合征（ACS）仍然是导致残疾和死亡的一个重要原因。急性冠脉事件发生后，复发的风险很大，尤其是在最初的90天内。2025年4月，澳大利亚国家心脏基金会和澳大利亚和新西兰心脏协会发布了一项新的澳大利亚临床指南，用于诊断和管理ACS。该指南包括ACS二级预防的建议。二级预防ACS的药物治疗包括抗血小板和抗凝血药物、脂质调节治疗、受体阻滞剂和肾素-血管紧张素拮抗剂治疗，以及在特定组中使用秋水仙碱和其他治疗。建议接种预防流感和其他呼吸道病原体的疫苗。非药物干预措施包括心脏康复、健康行为改变和心理健康状况筛查。还强调了提供支持坚持长期治疗的策略的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.